Curaleaf Holdings (CURLF) Asset Utilization Ratio (2020 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Asset Utilization Ratio of 0.44 for Q4 2024, up 39.81% year-on-year from 0.32 in Q1 2024, and up 34.75% on a QoQ basis from 0.33 in Q3 2024.
Curaleaf Holdings (CURLF) Asset Utilization Ratio (2020 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Asset Utilization Ratio for 5 consecutive years, with 0.44 the latest figure, recorded in Q4 2024.
- Quarterly Asset Utilization Ratio rose 39.81% year-over-year to 0.44 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.44 (up 39.81% YoY) and the FY2025 annual result came in at 0.44, down 0.84% from the prior year.
- Asset Utilization Ratio grew to 0.44 in Q4 2024 per CURLF's latest filing, from 0.33 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for CURLF reached as high as 1.72 in Q3 2022 and fell as low as 0.25 in Q4 2020.
- A 5-year average of 0.56 and a median of 0.51 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 426.83% — and 2023, when it slumped 75.96%.
- Year by year, Asset Utilization Ratio stood at 0.25 in 2020, then soared by 139.63% to 0.59 in 2021, then grew by 6.41% to 0.63 in 2022, then sank by 49.93% to 0.32 in 2023, then jumped by 39.81% to 0.44 in 2024.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.44, 0.33, and 0.32 for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.43 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.62 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.46 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.43 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.39 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.65 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.37 |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.44 |
| Sep 30, 2024 | 0.33 |
| Dec 31, 2023 | 0.32 |
| Sep 30, 2023 | 0.41 |
| Jun 30, 2023 | 0.67 |
| Mar 31, 2023 | 0.64 |
| Dec 31, 2022 | 0.63 |
| Sep 30, 2022 | 1.72 |
| Jun 30, 2022 | 0.59 |
| Mar 31, 2022 | 0.58 |
| Dec 31, 2021 | 0.59 |
| Sep 30, 2021 | 0.33 |
| Jun 30, 2021 | 0.28 |
| Dec 31, 2020 | 0.25 |